Sign In
Buy PMCB
$0.751
-0.0489 (-6.11%)
At Close: Jun 02, 2026
Nuvilex (NASDAQ:PMCB) Trading 5.3% Higher – Here’s Why
02:59am, Tuesday, 14'th Apr 2026
Nuvilex Inc. (NASDAQ: PMCB - Get Free Report) shares traded up 5.3% on Monday. The stock traded as high as $0.6949 and last traded at $0.6879. 85,294 shares were traded during trading, a decline of 45
Comparing Nuvilex (NASDAQ:PMCB) & Avadel Pharmaceuticals (NASDAQ:AVDL)
02:00am, Friday, 05'th Dec 2025
Avadel Pharmaceuticals (NASDAQ: AVDL - Get Free Report) and Nuvilex (NASDAQ: PMCB - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies b
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
09:15am, Tuesday, 25'th Nov 2025
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), fur
Nuvilex Inc. (NASDAQ:PMCB) Short Interest Up 95.4% in September
03:54am, Thursday, 23'rd Oct 2025
Nuvilex Inc. (NASDAQ: PMCB - Get Free Report) was the recipient of a large growth in short interest in September. As of September 30th, there was short interest totaling 433,100 shares, a growth of 95
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
09:15am, Wednesday, 20'th Aug 2025
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the closing of its previously announced $7 million financing. As of April 30
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
09:15am, Monday, 18'th Aug 2025
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) announced today that it has entered into a securities purchase agreement for a $7.0 million f
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
09:00am, Tuesday, 21'st May 2024
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (Nasdaq:MYMD) (“MyM
MyMD Pharmaceuticals Secures Strategic Investments
09:00am, Tuesday, 21'st May 2024
BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
08:30am, Wednesday, 15'th Nov 2023
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”)
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
09:15am, Tuesday, 31'st Oct 2023
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) provides an update on its investigation of its Cell-in-a-Box technology and initial next ste
PharmaCyte Biotech Announces Final Results of Tender Offer
09:15am, Thursday, 15'th Jun 2023
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces the final results of its previously announced tender offer to acquire up to
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
08:30am, Thursday, 11'th May 2023
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
09:00am, Thursday, 02'nd Feb 2023
LAS VEGAS--( BUSINESS WIRE )--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation techno
Topics to Include Continued Analysis of FDA's Clinical Hold on IND for Cell-in-a-Box® Topics to Include Continued Analysis of FDA's Clinical Hold on IND for Cell-in-a-Box®
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
08:30am, Monday, 15'th Aug 2022
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte and Iroquois have reached a settlement which includes appointing five new independent directors to PharmaCyte's reconstituted Board.
